NYSEAMERICAN:PTHS Pelthos Therapeutics (PTHS) Stock Price, News & Analysis $6.84 0.00 (0.00%) As of 11/17/2026 04:10 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Pelthos Therapeutics Stock (NYSEAMERICAN:PTHS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Pelthos Therapeutics alerts:Sign Up Key Stats Today's Range$6.76▼$7.1550-Day Range$6.84▼$23.5252-Week Range$6.76▼$32.51Volume74,257 shsAverage Volume67,709 shsMarket Capitalization$26.88 millionP/E RatioN/ADividend YieldN/APrice Target$48.33Consensus RatingModerate Buy Company Overview Pelthos Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for dermatologic conditions. Its portfolio includes ZELSUVMI (berdazimer) topical gel, an FDA-approved prescription treatment for molluscum contagiosum, a viral skin infection. ZELSUVMI is approved in the United States for adults and children aged one year and older. The topical treatment is designed for application at home, providing an option for patients and caregivers managing the condition. The company’s known commercial focus is the U.S. dermatology market. Publicly available information about its broader product pipeline and international operations is limited.AI Generated. May Contain Errors. Read More Pelthos Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks62nd Percentile Overall ScorePTHS MarketRank™: 3.10209249633 of 5 starsPelthos Therapeutics scored higher than 62% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingModerate Buy Consensus RatingPelthos Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and no sell ratings.Upside PotentialPelthos Therapeutics has a consensus price target of $48.33, representing about 606.6% upside from its current price of $6.84.Amount of Analyst CoveragePelthos Therapeutics has only been the subject of 4 research reports in the past 90 days.Read more about Pelthos Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Pelthos Therapeutics are expected to grow in the coming year, from ($14.49) to ($4.76) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Pelthos Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Pelthos Therapeutics is -0.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted4.95% of the float of Pelthos Therapeutics has been sold short.Short Interest Ratio / Days to CoverPelthos Therapeutics has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Pelthos Therapeutics has recently increased by 11.40%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPelthos Therapeutics does not currently pay a dividend.Dividend GrowthPelthos Therapeutics does not have a long track record of dividend growth. News and Social Media1.2 / 5News Sentiment-0.07 News SentimentPelthos Therapeutics has a news sentiment score of -0.07. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 17 news articles for Pelthos Therapeutics this week, compared to 2 articles on an average week. Company Ownership2.0 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Pelthos Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $28,434.00 in company stock.Percentage Held by Insiders16.40% of the stock of Pelthos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions77.96% of the stock of Pelthos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Pelthos Therapeutics' insider trading history. Receive PTHS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Pelthos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. PTHS Stock News HeadlinesPelthos Therapeutics Inc. (PTHS) - What Are Investment Firms Saying About This Stock?November 17 at 3:31 AM | americanbankingnews.comPelthos Therapeutics (PTHS) Stock Sees Fair Value Cut As Analysts Rework Launch And Merger RisksNovember 16 at 2:14 PM | finance.yahoo.comThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trades above $4,000 today. That gap means Washington's books show about $11 billion in gold that is actually worth more than $1 trillion. A bill in Congress would require repricing those reserves at market value. More than 60 million Americans qualify to move part of their savings into physical gold, tax-free and penalty-free, according to the 2026 Gold and Silver Guide.November 18 at 1:00 AM | Patriot Gold Group (Ad)Pelthos Therapeutics Q3 Earnings Call HighlightsNovember 16 at 4:13 AM | americanbankingnews.comAnalysts Offer Insights on NA Companies: Shopify (SHOP) and Pelthos Therapeutics (PTHS)November 15 at 5:11 PM | theglobeandmail.comAnalysts Offer Insights on NA Companies: Pelthos Therapeutics (PTHS) and Lineage Therap (LCTX)November 15 at 7:09 AM | theglobeandmail.comPelthos Therapeutics Shares Fall After Alliance Global Partners DowngradeNovember 13, 2026 | marketscreener.comMOppenheimer Adjusts Price Target on Pelthos Therapeutics to $59 From $64, Keeps Outperform RatingNovember 13, 2026 | marketscreener.comMSee More Headlines PTHS Stock Analysis - Frequently Asked Questions How have PTHS shares performed this year? Pelthos Therapeutics' stock was trading at $25.94 at the beginning of the year. Since then, PTHS stock has decreased by 73.6% and is now trading at $6.84. How were Pelthos Therapeutics' earnings last quarter? Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) issued its earnings results on Thursday, November, 12th. The company reported ($2.04) earnings per share for the quarter, beating analysts' consensus estimates of ($2.83) by $0.79. The firm earned $15.40 million during the quarter. Pelthos Therapeutics had a negative net margin of 123.24% and a negative trailing twelve-month return on equity of 432.23%. Read the conference call transcript. Who are Pelthos Therapeutics' major shareholders? Top institutional investors of Pelthos Therapeutics include AIGH Capital Management LLC (6.68%) and State Street Corp (0.28%). Insiders that own company stock include Ezra M Friedberg and Richard Malamut. View institutional ownership trends. How do I buy shares of Pelthos Therapeutics? Shares of PTHS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings11/12/2026Today11/18/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3w+) 1-Year History Nov 25 Feb 26 May 26 Aug 26 Nov 26 For the last 3 weeks, PTHS's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNYSEAMERICAN SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNYSEAMERICAN:PTHS CIK1919246 Webwww.pelthos.com Phone(919) 908-2422FaxN/AEmployees92Year FoundedN/APrice Target and Rating Average Price Target for Pelthos Therapeutics$48.33 High Price Target$64.00 Low Price Target$21.00 Potential Upside/Downside+606.6%Consensus RatingModerate Buy Rating Score (0-4)2.75 Research Coverage8 Analysts Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$43.32 million Net Margins-123.24% Pretax Margin-165.66% Return on Equity-432.23% Return on Assets-40.24% Debt Debt-to-Equity Ratio3.40 Current Ratio1.78 Quick Ratio1.10 Sales & Book Value Annual Sales$16.80 million Price / Sales1.60 Cash FlowN/A Price / Cash FlowN/A Book Value($1.57) per share Price / Book-4.36Miscellaneous Outstanding Shares3,930,000Free Float3,286,000Market Cap$26.88 million OptionableN/A Beta3.41 The 7 Best High-Yield Dividend Stocks for 2027Looking for higher dividend income in 2027? Discover seven high-yield dividend stocks with attractive payouts, proven dividend histories and growth potential.Get This Free Report This page (NYSEAMERICAN:PTHS) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersYour $7 scanner is waitingThe Instant Scanner is $7 in Bill Poulos's Black Friday sale. Every night it delivers a list showing which sto...Profits Run | SponsoredPentagon magnet restrictions take effect January 1, 2027A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It...OilPrice | SponsoredWhy I'm selling my Snapback Indicator for just $7For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indi...Base Camp Trading | SponsoredWhat the hell is going on?Porter Stansberry says President Trump is quietly replacing the U.S. dollar without a vote in Congress, and th...Porter & Company | SponsoredYour Social Security check is scheduled for a 22% cutThe U.S. now borrows money just to pay interest on money it already borrowed, a pattern economists call a debt...American Alternative | SponsoredYour father's savings lost half their value after 1971.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThis Could Be the Biggest Monetary Shift in 50 YearsThe U.S. government still values its gold reserves at $42 an ounce, a price set by Congress in 1973. Gold trad...Patriot Gold Group | SponsoredEvery Starlink dish pays this stockThere's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Pelthos Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Pelthos Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.